Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cancer Treatment Reviews|October 12, 2018
Molecular imaging to enlighten cancer immunotherapies and underlying involved processesElly L van der Veen, Frederike Bensch, Andor W J M Glaudemans, et al.
Pharmacology & Therapeutics|February 12, 2014
HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targetingArjan Kol, Anton G T Terwisscha van Scheltinga, Hetty Timmer-Bosscha, et al.
Cancers|August 14, 2025
Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective StudyChris W Govaerts, Miranda C A Kramer, Ingeborg Bosma, et al.
Cancers|February 27, 2026
Correction: Govaerts et al. Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study. Cancers 2025, 17, 2425Chris W Govaerts, Miranda C A Kramer, Ingeborg Bosma, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 31, 2018
89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work upFrederike Bensch, A H Brouwers, M N Lub-de Hooge, et al.
European Journal of Pharmacology|April 3, 2013
Molecular imaging for monitoring treatment response in breast cancer patientsFrederike Bensch, Michel van Kruchten, Laetitia E Lamberts, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2023
The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR studyBirgitta I Hiddinga, Dirk-Jan Slebos, T David Koster, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2020
Assessment of Bone Lesions with 18F-FDG PET Compared with 99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer ManagementSuzanne C van Es, Ton Velleman, Sjoerd G Elias, et al.
Theranostics|September 15, 2018
Comparative biodistribution analysis across four differentFrederike Bensch, Michaël M Smeenk, Suzanne C van Es, et al.
The American Journal of Surgical Pathology|July 9, 2019
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 ResultsSuzanne C van Es, Bert van der Vegt, Frederike Bensch, et al.
Pageof 2